Left ventricular (LV) mass progressively increases throughout life, reaching its greatest magnitude in senescence. In the normotensive elderly, left ventricular hypertrophy (LVH) is mostly a consequence of a degenerative process in connective tissue. In hypertensive patients, LVH results from an increase in muscle mass and fibrotic tissue. LVH by echocardiographic criteria can be found in up to 50% of elderly patients with hypertension.
Left ventricular hypertrophy
Unlike other organs, the heart does not atrophy with age; in fact even in normotensive subjects left ventricular (LV) mass progressively increases throughout life. Various studies have documented an increase in wall thickness with age in the presence of unchanged chamber volume. [1] [2] [3] In addition to the increased size of the myocytes, the aging heart is characterised by a high rate of degenerative age-associated findings such as lipid deposition, tubular dilatation and decreased mitochondrial oxidative phosphorylation. 3, 4 Concomitantly, the amount of elastic tissue, collagen and fat increases. Therefore, even in normotensive subjects LV mass progressively increases throughout life, reaching its greatest magnitude in senescence. The prevalence of electrocardiographically diagnosed LV hypertrophy (ECG-LVH) in the population-based studies has been described as 4.2% to 16 .9% according to the Minnesota criteria. 5 The Cardiovascular Health Study, 6 in which electrocardiograms of 5150 adults older than 65 years were analysed, showed that according to the Minnesota code, LVH was found in 4.1% of women and 4.3% of men. In the Framingham study the prevalence of ECG-LVH rose linearly with age. 7 
Hypertension
Increase in blood pressure (BP) is another feature of aging. The degenerative changes in the arterial wall as well as an increase in the ratio of the sensitivity Correspondence: Dr FH Messerli, Ochsner Clinic, 1514 Jefferson Highway, New Orleans, Louisiana 70121, USA LV function. Conceivably, an increase in interstitial fibrosis and cross-linking collagen in the senescent heart is responsible for an increase in myocardial stiffness and diastolic abnormalities.
Regression of LVH has been demonstrated not only to improve left ventricular filling and coronary reserve but also to diminish cardiac arrhythmias. Although few studies have demonstrated that the reduction of LV mass is associated with better cardiovascular prognosis, it seems reasonable to consider it a goal of antihypertensive therapy. Of all antihypertensive agents, angiotensin-converting-enzyme inhibitors seem to be the most powerful in reducing LV mass.
and/or density of vasoconstrive receptors (alpha) to vasorelaxing receptors (beta) lead to the decrease in compliance of large arteries and higher peripheral resistance. 3 Other factors possibly contributing to increased BP in the elderly population are decreased oestrogen production in women, increased level of catecholamines, obesity, high prevalence of renal insufficiency and frequent consumption of nonsteroidal anti-inflammatory agents. The prevalence of hypertension in the elderly may reach 60% of the general population.
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LVH and hypertension
LVH by echocardiographic criteria can be found in up to 50% of elderly patients with hypertension. 9 The hypertrophic senescent heart in the morphometric study of Olivetti et al 10 was characterised by an increase in average myocyte cell volume per nucleus and an augmentation in the total number of myocyte nuclei in the ventricle myocardium. These processes were associated with 95% enlargement of the myocardial interstitium. In hypertensive patients irrespective of age, LVH is an adaptation to an increased end systolic wall stress and by thickening of LV walls leads to its normalisation. 2, 11 In a stepwise multiple analysis of a very heterogeneous population of 171 hypertensive patients, we demonstrated that age was an independent determinant of posterior and septal wall thickness and of LV mass. 11 Posterior wall thickness increased by about 25% between the 2nd and 7th decade of life, and the ratio of radius to wall thickness declined, indicating LVH of the concentric type. Arterial pressure in this study correlated the best with the relative wall thickness and chamber volume. BP level remains the major determinant of LVH even in the elderly, and the correlation of electrocardiographic LVH has been demonstrated to be closer with systolic than diastolic or pulse pressure. The Cardiovascular Health Study showed a significant direct correlation between the LV mass and age as well as systolic BP (SBP). 6 This occurrence of LVH in association with high SBP was confirmed by the findings of the European Working Party on Hypertension in the Elderly in which the electrocardiographic measures of LVH correlated significantly better with systolic than diastolic BP (DBP). 12 In a Dutch study by van den Hoogen et al 13 in which the diagnosis of LVH was based on the Minnesota Code, 21% of 1373 hypertensive subjects had LVH with or without repolarisation abnormalities. A logistic regression analysis showed the influence on the occurrence of LVH of the following parameters: being male, age Ͼ65 years, SBP Ͼ160 mm Hg and DBP Ͼ105 mm Hg.
LVH was traditionally considered a result of an adaptive physiologic process serving to compensate for an increased afterload. However, data from the Framingham cohort indicated that patients with LVH were at greater risk for sudden death and other complications leading to increased cardiovascular morbidity and mortality than subjects with normal hearts. 7 Subsequently, numerous epidemiological longitudinal studies showed that ECG-LVH or echocardiographically diagnosed LVH was associated with increased risk of cardiovascular complications such as myocardial infarction, angina, sudden death, congestive heart failure and stroke.
14-17 The brain ischaemic complications are also more frequent in this group of patients. Kawamoto et al 18 showed that ECG-LVH had highly predictive value for the presence of multi-lacunar brain lesions as diagnosed by magnetic resonance imaging. Moreover, Aronow et al 17 in a prospective study of 410 elderly subjects demonstrated that ECG-LVH was an independent risk factor for atherothrombotic brain infarction.
Consequences of LVH
LVH in arterial hypertension in the elderly is histologically characterised by myocyte hypertrophy, advanced myocardial fibrosis, and structural changes of the intramural coronary arteries. These structural alterations originate and maintain a process of myocardial underperfusion which can provoke a functional decrease of the myocardial performance, a loss of contractile proteins, an increase in interstitial fibrosis, and an overall decrease in contractile function in long-standing cardiac hypertrophy.
LVH and cardiac ischaemia
Symptoms of angina pectoris can frequently be found in patients with hypertension and LVH in the presence of normal coronary arteriograms. 14, 19 A reduced vasodilator capacity due to thickening of intramyocardial arteriolar walls, increased fibrosis and finally increased coronary artery resistance can be found in hypertensive subjects with LVH. Thus, the decreased ratio of subendocardial to epicardial blood flow in the left ventricle with increased oxygen demand will often result in silent or even overt myocardial ischemia.
LVH carries significant risk not only for patients without overt coronary artery disease but also for survivors of myocardial infarction. Behar et al 20 followed 4720 consecutive hospital survivors of acute myocardial infarction, most of whom were elderly. Mean age of subjects with ECG-LVH was 67.2 vs 61.4 years in counterparts free of LVH. Patients with ECG-LVH had a higher rate of congestive heart failure on admission or that developed during their stay in coronary care units. The 1-and 5-year mortality rates were 19.7 and 46.6% among patients with LVH vs 8.7 and 26.2%, respectively, in patients without this finding. The results of this study showed that the presence of ECG-LVH on the discharge ECG of survivors from acute myocardial infarction almost doubles short-and long-term mortality.
LVH and arrhythmias
We demonstrated that hypertensive patients with LVH had more frequent and complex ventricular ectopy than those with a normal or less hypertrophied myocardium. 21 In the group with LVH, not only were premature ventricular contractions 40 to 50 times more prevalent but so were Lown's class III and class IV ectopies such as coupled and multifocal beats. Ever since our first observation, a variety of other studies have attested to the arrhythmogenicity of LVH (for review see ref 22) . Mutatis mutandis, in a study of elderly subjects with hypertension, we confirmed that patients with more severe and/or more frequent ventricular arrhythmias had higher LV mass, LV mass index and increased walls thickness. 23 Palatini et al 24 found that impaired LV filling in hypertensive LVH may serve as a marker of the presence of an arrhythmogenic substrate. In a study involving 107 hypertensives with echocardiographic LVH and 70 controls, 25% of the hypertensive subjects and 6% of the controls presented with late potentials on signal averaged electrocardiography (P Ͻ 0.0001). The hypertensive subjects with late potentials had a higher prevalence of ventricular tachycardia (33%) than those without late potentials (13%, P = 0.035). In a multivariate analysis only LV filling as measured by the early to atrial filling velocity ratio (E/A ratio) was related to the presence or absence of either late potentials or ventricular tachycardia. The authors concluded that impaired LV filling was the main marker for the arrhythmogenic substrate present in this disease. Patchy or diffuse myocardial fibrosis could represent the common denominator between LV filling and arrhythmogenicity.
LVH and LV dysfunction
The findings of prolongation of diastolic filling with increased LV mass were observed in young as well as in elderly hypertensive patients and have been documented in several studies. [25] [26] [27] Impaired diastolic filling has been found to be a very early sign of hypertensive heart disease which occurs even before an increase in LV mass can be identified. In our study, older subjects with normal LV mass presented with impairment of LV relaxation similar to that of younger patients with LVH. 28 Conceivably, an increase in interstitial fibrosis and cross-linking collagen in the senescent heart is responsible for an increase in myocardial stiffness and diastolic abnormalities. Higher LV end-diastolic pressure may in some cases lead to pulmonary oedema in spite of well-preserved systolic function as it was described by Topol et al. 29 Although the number of studies comparing LV function in aged patients with and without LVH is limited, the appearance of LVH may be associated primarily with deterioration in diastolic function and consequently with decline of contractile parameters.
LVH also has been documented to be associated with a decrease in contractility. The Cardiovascular Health Study performed in the free living elderly population demonstrated that age as well as hypertension and clinical coronary artery disease are the independent predictors of LV ejection fraction abnormalities. 30 In the previously cited crosssectional study, we demonstrated a disparate effect of LV mass on the indices of LV systolic function in the young and elderly hypertensive subjects. 28 Thus, as LVH progresses, contractile function, as evaluated by the ejection fraction, fractional fibre shortening or velocity of circumferential fibre shortening, becomes progressively impaired only in older subjects. 31 It suggests that degenerative changes in the myocardium, presumably associated with aging, were probably responsible for the observed deterioration in ejection fraction, velocity of circumferential fibre and fractional fibre contractility in the elderly hypertensives. Impaired LV function seems to have prognostic implications even in the elderly; in the recently published Helsinki Ageing Study, an increase in LV mass, lower LV shortening fraction and the presence of aortic or mitral valve lesions were associated with increased cardiovascular risk in the 75-86 year old subjects.
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Therapeutic assumptions
The number of studies demonstrating that decrease in LV mass is associated with improved cardiovascular prognosis is still very limited. 33 Recently Muiesan et al 34 demonstrated in the population of 151 subjects followed for 7-13 years that regression of LVH was associated with significantly better prognosis in comparison with subjects with newly developed or continual LVH. Similar results were shown by data from Framingham (based on electrocardiography) and the Cornell group. 35, 36 In the analysis of the 10 studies performed at Ochsner Clinic, we showed that a fall in BP and drug class were the main predictors of the decrease in LV mass. 37 Conversely, advanced age and black race were negatively related to the decrease in wall thickness.
The inhibition of angiotensin-converting enzyme (ACE) has been shown in experimental studies to modify cellular processes by preventing polyploidisation involved in myocyte growth in arterial hypertension. 38 Moreover, as the cardiac fibroblast expresses mRNA for types I and III collagens, the major fibrillar collagens in the heart, the increase in collagen synthesis in fibroblasts stimulated through angiotensin II could be completely abolished by ACE inhibitors or Ang II type 1 receptor antagonists, respectively. 39 Indeed, anti-hypertensive therapy with certain specific drugs, ie, ACE inhibitors and calcium antagonists, has been shown not only to reduce LV mass but to diminish ventricular ectopy and improve LV function concomitantly.
The serum concentrations of two procollagenderived peptides, procollagen type III amino terminal peptide and procollagen type I carboxy terminal peptide, have been proposed as useful markers of the tissue synthesis of collagen type III and type I, respectively. Diez et al 40 demonstrated in subjects with hypertension treated with an ACE inhibitor (lisinopril) that normalisation in BP, amelioration of diastolic filling, regression of LV mass index, and a diminution in the number of ventricular arrhythmias were associated with significantly decreased concentrations of serum procollagen type III amino terminal peptide and procollagen type I carboxy terminal peptide. Their findings suggest that tissue synthesis of collagen type III and type I is abnormally increased in essential hypertension and can be normalised by ACE inhibition.
ACE inhibitors seem to reduce LVH to a somewhat greater extent than other anti-hypertensive agents. 33, 41, 42 Despite the fact that plasma renin activity is often low in elderly hypertensive patients, all ACE inhibitors have been shown to lower BP efficaciously and safely in the geriatric population. 43 This demonstrates that the anti-hypertensive and antiproliferative effect of ACE inhibition is not solely dependent on circulating plasma renin activity. Since ACE inhibitors lower arterial pressure by decreasing total peripheral resistance while maintaining or enhancing systemic and regional blood flow (lower both preload and afterload to the left ventricle), they are the agents of choice in hypertensive patients with congestive heart failure of systolic dysfunction. 43 Diuretics reduce LV mass by decreasing the LV diastolic diameter and to a lesser extent by reducing LV wall thickness. 44 Therefore, they can be used but only in small doses (preferably thiazide with potassium-sparing agent) as first-line anti-hypertensive agents in elderly hypertensive patients, especially when fluid volume overload is present.
Calcium antagonists lower arterial pressure by reducing total peripheral resistance 41 and therefore seem to be agents of choice for elderly patients. Dihydropyridine calcium antagonists in slowrelease formulation are excellent agents in elderly hypertensive patients with hypertensive heart disease, particularly when ischaemia is present.
Non-dihydropyridine calcium antagonists, particularly verapamil, are also agents of choice, especially in patients with heart failure secondary to impaired LV filling or diastolic dysfunction which is a common sequela of long-standing hypertension and LVH. 45 Verapamil has also been shown to be superior to a beta-blocker in reduction of LVH without depressing LV function in elderly subjects. 46 In a recently published study, Arrighi et al 47 showed that verapamil enhances LV diastolic filling in normotensive middle-aged and elderly subjects without affecting systolic function. In the elderly, peak filling rate (expressed in fractional stroke volume per second) increased with verapamil from 4.3 ± 1.0 to 5.7 ± 1.0 (P Ͻ 0.01), and time to peak filling rate decreased from 185 ± 31 to 147 ± 15 msec (P Ͻ 0.01).
Beta-blockers and angiotensin II receptor antagonists have been found to be less effective in reducing LVH; however, in the latter case more studies are needed. 41, 42, [48] [49] [50] Beta-blockers may be considered for treatment of hypertensive patients presenting with coronary artery disease. 51 
